Zurcher Kantonalbank Zurich Cantonalbank Has $1.65 Million Position in Doximity, Inc. (NASDAQ:DOCS)

Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Doximity, Inc. (NASDAQ:DOCS - Free Report) by 31.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 30,879 shares of the company's stock after purchasing an additional 7,351 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank's holdings in Doximity were worth $1,649,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of DOCS. Oppenheimer & Co. Inc. raised its stake in Doximity by 139.2% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 35,635 shares of the company's stock worth $1,553,000 after purchasing an additional 20,740 shares in the last quarter. KBC Group NV increased its holdings in Doximity by 22.9% in the 3rd quarter. KBC Group NV now owns 3,296 shares of the company's stock valued at $144,000 after buying an additional 614 shares during the period. Natixis Advisors LLC increased its holdings in Doximity by 43.5% in the 3rd quarter. Natixis Advisors LLC now owns 31,815 shares of the company's stock valued at $1,386,000 after buying an additional 9,644 shares during the period. Thrivent Financial for Lutherans increased its holdings in Doximity by 5.0% in the 3rd quarter. Thrivent Financial for Lutherans now owns 30,991 shares of the company's stock valued at $1,350,000 after buying an additional 1,474 shares during the period. Finally, Prospera Private Wealth LLC bought a new position in Doximity in the 3rd quarter valued at about $133,000. Institutional investors and hedge funds own 87.19% of the company's stock.

Doximity Stock Performance

Shares of NASDAQ DOCS traded up $0.24 during midday trading on Friday, reaching $63.01. The stock had a trading volume of 4,005,753 shares, compared to its average volume of 1,880,534. The firm has a market cap of $11.76 billion, a price-to-earnings ratio of 63.01, a price-to-earnings-growth ratio of 4.10 and a beta of 1.34. Doximity, Inc. has a twelve month low of $22.96 and a twelve month high of $85.21. The company's 50 day moving average price is $64.20 and its 200 day moving average price is $53.21.

Remove Ads

Insider Transactions at Doximity

In other news, Director Timothy S. Cabral sold 20,000 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $57.62, for a total value of $1,152,400.00. Following the transaction, the director now owns 6,360 shares in the company, valued at approximately $366,463.20. The trade was a 75.87 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 37.40% of the company's stock.

Analyst Ratings Changes

Several research firms have commented on DOCS. Piper Sandler raised shares of Doximity from a "neutral" rating to an "overweight" rating and raised their target price for the company from $31.00 to $78.00 in a report on Friday, February 7th. Mizuho raised their target price on shares of Doximity from $55.00 to $65.00 and gave the company a "neutral" rating in a report on Monday, February 10th. Needham & Company LLC raised their target price on shares of Doximity from $65.00 to $82.00 and gave the company a "buy" rating in a report on Friday, February 7th. Wells Fargo & Company reaffirmed an "equal weight" rating on shares of Doximity in a report on Friday, February 7th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Doximity from $30.00 to $48.00 and gave the company a "neutral" rating in a report on Thursday, November 21st. Eleven analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $64.22.

Doximity Company Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.